No Drug Has Ever Reversed Cartilage Loss. Stanford May Have Just Changed That.

A Stanford Medicine study published in Science has identified the first drug capable of actually reversing cartilage loss, not just slowing it. The target is a protein the body produces more of as it ages. And the early human tissue data are remarkably encouraging.

Presented By Our Partners

For as long as orthopedic medicine has existed, osteoarthritis has been treated as a one-way street. Cartilage wears down, pain and stiffness set in, and the only meaningful interventions are either managing symptoms or eventually replacing the joint entirely. No approved drug has ever demonstrated the ability to slow, stop, or reverse the underlying loss of cartilage. That clinical reality has held for decades despite enormous investment and repeated failed trials.

A study published June 12, 2026, in Science may represent the first credible challenge to that paradigm. Researchers at Stanford Medicine identified a protein that accumulates in joints as the body ages, directly suppresses cartilage repair, and can be blocked by a small molecule drug. In aged mice, that drug restored cartilage the animals had already lost. In a model mimicking ACL tears, it prevented post-injury arthritis from developing. And when human cartilage samples taken during knee replacement surgeries were exposed to the treatment, the tissue began generating new articular cartilage within a week.

“Until now, there has been no drug that directly treats the cause of cartilage loss,” said Nidhi Bhutani, PhD, associate professor of orthopedic surgery at Stanford Medicine and co-senior author of the study. “But this gerozyme inhibitor causes a dramatic regeneration of cartilage beyond that reported in response to any other drug or intervention.”

The Scale of the Osteoarthritis Problem

Osteoarthritis is the most common form of arthritis, affecting roughly one in five adults in the United States. It is primarily a disease of cartilage: the smooth, slippery hyaline cartilage that lines joints such as the knees, hips, shoulders, and ankles gradually breaks down, leaving bones to grind against each other. The result is chronic pain, stiffness, swelling, and, in severe cases, near-total loss of joint function.

The economic footprint of osteoarthritis is staggering. Direct healthcare costs in the US alone are estimated at approximately $65 billion per year, driven largely by pain management, physical therapy, and the roughly one million joint replacement surgeries performed annually. Those replacements work reasonably well, but they carry real risks, require long rehabilitation periods, and typically need to be revised within 15 to 20 years.

What has never existed is a disease-modifying therapy. Patients can take anti-inflammatories, receive corticosteroid injections, try hyaluronic acid supplementation, and pursue physical therapy. None of these approaches address the biology driving cartilage loss. The new Stanford research targets that biology directly.

What Is a Gerozyme?

The Stanford team’s work centers on a class of proteins they have termed gerozymes. The term captures a key property: these proteins become more abundant as the body ages, and as they accumulate, they suppress tissue function. They are, in essence, molecular brakes that the aging body applies more aggressively over time.

The specific gerozyme at the heart of this study is 15-hydroxyprostaglandin dehydrogenase, known as 15-PGDH. Its primary function is to break down a signaling molecule called prostaglandin E2, or PGE2. That may sound like a small biochemical detail, but PGE2 plays a broad and critical role in tissue regeneration. When 15-PGDH rises with age, PGE2 falls, and regenerative capacity falls with it.

Helen Blau, PhD, professor of microbiology and immunology at Stanford and the Donald E. and Delia B. Baxter Foundation Professor, directs the Baxter Laboratory for Stem Cell Biology and is the study’s other senior author. Her laboratory first identified gerozymes in 2023 and initially demonstrated their role in age-related muscle decline. When 15-PGDH was blocked in aged mice, their muscles regained mass and endurance. When it was artificially elevated in young mice, their muscles deteriorated as though the animals were old. Subsequent research linked 15-PGDH to regeneration in bone, nerve, blood, colon, and liver tissues.

The obvious question was whether the same mechanism operated in cartilage.

What Stanford Actually Did

The research team, led by Mamta Singla, PhD, instructor of orthopedic surgery at Stanford, and Yu Xin (Will) Wang, PhD, now an assistant professor at the Sanford Burnham Prebys Medical Discovery Institute in San Diego, began by comparing cartilage from young and old mice. The finding was clear: levels of 15-PGDH approximately doubled with age in cartilage tissue.

To test whether blocking this protein could reverse the damage, the team treated aged mice with a small molecule drug that inhibits 15-PGDH activity. They used two delivery methods: injections into the abdomen, which exposed the entire body to the treatment, and injections delivered directly into the knee joint. Both produced striking results.

Cartilage that had become thinner and less functional with age grew measurably thicker across the joint surface. Critically, the researchers confirmed that the regenerated tissue was hyaline cartilage, the type that lines joints and is specifically damaged in osteoarthritis, rather than fibrocartilage, a structurally inferior substitute that the body sometimes produces in repair attempts and that does not restore normal joint function.

“Cartilage regeneration to such an extent in aged mice took us by surprise,” Bhutani said. “The effect was remarkable.”

Preventing Arthritis After ACL-Type Injuries

The team extended their investigation to a mouse model designed to mimic ACL tears, one of the most common serious joint injuries in athletic populations. ACL injuries are surgically repairable, but roughly half of affected individuals develop osteoarthritis in the damaged joint within approximately 15 years, a consequence of the inflammatory cascade triggered by the injury itself.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The data were compelling. Untreated mice developed elevated 15-PGDH levels following injury, approximately twice the levels seen in uninjured animals, and progressed to measurable osteoarthritis within four weeks. Mice that received the gerozyme inhibitor twice weekly for four weeks post-injury showed dramatically lower rates of arthritis development. They also walked more normally and bore more weight on the injured limb.

This has implications beyond aging-related joint decline. If a drug can be administered shortly after a significant joint injury to prevent the inflammatory processes that culminate in osteoarthritis years later, it changes the calculus for acute injury management entirely.

A New Model of Tissue Regeneration

One of the more surprising findings in the study concerns the mechanism of cartilage regeneration itself. In most tissues, regeneration is understood to occur through stem cells: undifferentiated progenitor cells that proliferate and differentiate into the specialized cells the tissue needs. Researchers looking for cartilage repair have therefore spent decades searching for cartilage stem cells, with limited success.

What this study found is something different. Rather than stem cell proliferation, 15-PGDH inhibition appears to shift the gene expression of existing cartilage cells, called chondrocytes, toward a more youthful state. The cells do not need to be replaced. They need to be reprogrammed.

“This is a new way of regenerating adult tissue, and it has significant clinical promise for treating arthritis due to aging or injury,” Blau said. “We were looking for stem cells, but they are clearly not involved. It’s very exciting.”

The cellular data support this interpretation in striking detail. In aged cartilage, a subpopulation of chondrocytes that produced 15-PGDH and expressed genes linked to cartilage breakdown represented approximately 8% of all cells. After treatment, that population fell to 3%. A separate population associated with fibrocartilage production dropped from 16% to 8%. Meanwhile, the population of cells involved in building hyaline cartilage and maintaining the extracellular matrix nearly doubled, rising from 22% to 42%.

These are not modest shifts. The treatment appears to fundamentally reorganize the cellular composition of aging cartilage tissue.

Human Cartilage Also Responded

The findings in mice, while compelling, represent only one step toward clinical relevance. The team went further, testing the 15-PGDH inhibitor on human tissue samples obtained from patients undergoing total knee replacement surgery for osteoarthritis.

After one week of treatment, the human samples showed fewer cartilage-degrading cells, reduced activity of genes linked to cartilage breakdown and fibrocartilage production, and measurable generation of new articular cartilage.

“The mechanism is quite striking and really shifted our perspective about how tissue regeneration can occur,” Bhutani said. “It’s clear that a large pool of already existing cells in cartilage are changing their gene expression patterns. And by targeting these cells for regeneration, we may have an opportunity to have a bigger overall impact clinically.”

The human tissue validation is important because it provides biological plausibility for eventual clinical translation. The same molecular machinery appears to be operative in human cartilage, not just in rodent models.

The Road to Clinical Use

The most immediately actionable data point in the entire study may be this: an oral version of a 15-PGDH inhibitor has already completed Phase 1 clinical trials for age-related muscle weakness, demonstrating safety and biological activity in healthy volunteers. The compound, known as MF-300 and developed by Epirium Bio (a company co-founded by Blau), cleared its initial safety bar in September 2025.

That matters enormously. One of the most common failure points in translating animal research to human medicine is safety. The 15-PGDH inhibitor class has already crossed that threshold in people, even if the approved indication is not yet cartilage-specific. Regulatory pathways for a new indication in joint repair would likely benefit from that established safety profile.

Blau and Bhutani have been explicit about their hopes for next steps. “Phase 1 clinical trials of a 15-PGDH inhibitor for muscle weakness have shown that it is safe and active in healthy volunteers,” Blau said. “Our hope is that a similar trial will be launched soon to test its effect in cartilage regeneration. We are very excited about this potential breakthrough. Imagine regrowing existing cartilage and avoiding joint replacement.”

The research was funded by the National Institutes of Health, the Baxter Foundation for Stem Cell Biology, the Li Ka Shing Foundation, the Stanford Cardiovascular Institute, the Milky Way Research Foundation, and the Canadian Institutes of Health Research. Blau, Bhutani, and several co-authors are named inventors on Stanford University patent applications related to 15-PGDH inhibition for cartilage repair and tissue rejuvenation, which have been licensed to Epirium Bio.

Why This Is Different From Everything That Came Before

It is worth pausing to contextualize what makes this approach distinct from the long history of attempts to treat osteoarthritis at the disease level.

Prior strategies have generally pursued one of two paths. The first involves targeting inflammation, the secondary process triggered by cartilage breakdown. Anti-inflammatory drugs can reduce pain and slow some downstream damage, but they do not address the loss of cartilage itself. The second path involves attempting to stimulate cartilage production, either through platelet-rich plasma injections, growth factor delivery, stem cell therapies, or tissue engineering. These approaches have shown mixed results in trials and have not produced a treatment capable of regrowing the structural cartilage that osteoarthritis destroys.

What the Stanford study identifies is something upstream of all of those approaches: a molecular switch, whose activity increases with age, that determines whether cartilage cells enter a regenerative or degenerative program. By blocking that switch, the researchers did not stimulate one repair mechanism. They shifted the entire gene expression profile of cartilage tissue toward a younger, healthier state.

There is also a systemic dimension to this discovery. Because 15-PGDH is a gerozyme that suppresses regeneration across multiple tissue types, its inhibition may have broad consequences beyond joints. The same protein appears to govern age-related decline in muscle, bone, nerve tissue, and the blood-forming system. A drug targeting it may ultimately address several components of aging-related physical decline simultaneously.

That is a speculative possibility at this stage, but it is worth noting that the oral formulation already in trials was developed for muscle weakness, not joints, and the same mechanism is at play in both tissues. The breadth of the biology here is unusual.

What This Means For You

More than 32 million Americans live with osteoarthritis today. If you are among them, or if you have experienced a significant joint injury that puts you at elevated risk, this research is worth understanding carefully and following closely.

The most important near-term implication is that a mechanism has now been validated in human tissue. Previous breakthroughs in cartilage research have often failed to replicate from animal models to people. The fact that samples from patients undergoing knee replacement surgery responded to 15-PGDH inhibition within a single week of treatment is meaningful evidence that the biology is not rodent-specific.

From a longevity standpoint, the gerozyme framework represents something genuinely new. We have long known that the body’s regenerative capacity declines with age, but we have lacked molecular-level explanations for why specific tissues become unable to repair themselves. The identification of a protein that rises with age and actively suppresses repair gives medicine a tractable target. It also suggests that what we have accepted as inevitable age-related tissue decline may be, at least in part, pharmacologically reversible.

In the near term, if you have knee or hip osteoarthritis and are weighing joint replacement surgery, it is worth having a conversation with your orthopedic surgeon about the pace of clinical development for disease-modifying therapies. Joint replacements are often not urgent decisions, and the landscape of treatment options could look meaningfully different within three to five years if 15-PGDH inhibitor trials advance successfully.

For those focused on prevention, the ACL injury findings carry a particular message. The period immediately following a joint injury appears to be a critical window in which the inflammatory cascade that eventually produces arthritis can potentially be interrupted. This has always been the theory behind aggressive post-injury rehabilitation protocols, but a pharmacological intervention that could be administered in the weeks following injury and prevent arthritis from developing represents a fundamentally new category of tool.

And for the 70 million Americans over 65 who have not yet been diagnosed with osteoarthritis but whose cartilage is quietly thinning with each passing year, the broader message of this research is that the biology of that decline may be targetable before the damage becomes symptomatic. The same drug that reverses established cartilage loss in aged mice also prevented post-injury arthritis entirely. A preventive application, delivered to higher-risk individuals before severe joint disease develops, is a natural next clinical question.

The study was published in Science (Volume 391, Issue 6789, 2026) under the title “Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration,” authored by Mamta Singla, Yu Xin Wang, Elena Monti, Yudhishtar Bedi, Pranay Agarwal, Shiqi Su, Sara Ancel, Maiko Hermsmeier, Nitya Devisetti, Akshay Pandey, Mohsen Afshar Bakooshli, Adelaida R. Palla, Stuart Goodman, Helen M. Blau, and Nidhi Bhutani.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.